Literature DB >> 27099573

Budesonide Extended-Release in Patients With Mild to Moderate Ulcerative Colitis.

Asher Kornbluth1.   

Abstract

Entities:  

Year:  2015        PMID： 27099573      PMCID： PMC4836579     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation.

Authors:  M Brunner; S Ziegler; A F D Di Stefano; P Dehghanyar; K Kletter; M Tschurlovits; R Villa; R Bozzella; G Celasco; L Moro; A Rusca; R Dudczak; M Müller
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

2.  Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.

Authors:  William J Sandborn; Simon Travis; Luigi Moro; Richard Jones; Theres Gautille; Robert Bagin; Michael Huang; Phil Yeung; E David Ballard
Journal:  Gastroenterology       Date:  2012-08-11       Impact factor: 22.682

3.  Gastrointestinal pH profiles in patients with inflammatory bowel disease.

Authors:  A G Press; I A Hauptmann; L Hauptmann; B Fuchs; M Fuchs; K Ewe; G Ramadori
Journal:  Aliment Pharmacol Ther       Date:  1998-07       Impact factor: 8.171

4.  Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.

Authors:  Simon P L Travis; Silvio Danese; Limas Kupcinskas; Olga Alexeeva; Geert D'Haens; Peter R Gibson; Luigi Moro; Richard Jones; E David Ballard; Johan Masure; Matteo Rossini; William J Sandborn
Journal:  Gut       Date:  2013-02-22       Impact factor: 23.059
  4 in total
  1 in total

Review 1.  Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment.

Authors:  Wunan Zhang; Cecilia Bohns Michalowski; Ana Beloqui
Journal:  Front Bioeng Biotechnol       Date:  2021-06-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.